Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18911297 | COMPOSITION AND KIT FOR DETECTING MYCOPLASMA | October 2024 | June 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18442644 | COMPOSITIONS AND METHODS FOR DETECTING OR QUANTIFYING HUMAN PARAINFLUENZA VIRUS 2 | February 2024 | June 2025 | Allow | 16 | 1 | 0 | No | No |
| 18442591 | COMPOSITIONS AND METHODS FOR DETECTING OR QUANTIFYING HUMAN PARAINFLUENZA VIRUS 4 | February 2024 | June 2025 | Allow | 16 | 2 | 0 | No | No |
| 18536784 | Method to Screen For a Mutant Within a Population of Organisms By Applying a Pooling and Splitting Approach | December 2023 | June 2025 | Allow | 18 | 0 | 1 | No | No |
| 18384527 | COMPOSITIONS AND METHODS FOR SAMPLE PROCESSING | October 2023 | May 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18364944 | METHODS AND SYSTEMS FOR SAMPLE ANALYSIS | August 2023 | January 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18185738 | METHODS FOR DETECTING FUNGI IN TURF GRASS WITH A LAMP ASSAY HAVING NOVEL PRIMER SETS | March 2023 | June 2025 | Allow | 27 | 1 | 1 | No | No |
| 18061712 | COMPOSITIONS AND METHODS FOR DETECTING A BIOLOGICAL CONTAMINANT | December 2022 | April 2025 | Allow | 28 | 1 | 0 | No | No |
| 18045927 | Real Time Cleavage Assay | October 2022 | April 2025 | Allow | 30 | 1 | 0 | No | No |
| 17954618 | Diagnostic Assays for Detecting, Quantifying, and/or Tracking Microbes and Other Analytes | September 2022 | April 2025 | Abandon | 30 | 0 | 1 | No | No |
| 17807345 | SOYBEAN EVENT DP-305423-1 AND COMPOSITIONS AND METHODS FOR THE IDENTIFICATION AND/OR DETECTION THEREOF | June 2022 | June 2025 | Allow | 36 | 1 | 1 | No | No |
| 17716619 | FECAL MICROBIAL BIOMARKERS FOR NON-ALCOHOLIC FATTY LIVER DISEASE | April 2022 | June 2025 | Allow | 39 | 4 | 1 | Yes | No |
| 17702152 | TARGET REPORTER CONSTRUCTS AND USES THEREOF | March 2022 | May 2025 | Allow | 38 | 1 | 0 | No | No |
| 17690951 | EXTRACTION-FREE PATHOGEN TESTING METHODS | March 2022 | March 2025 | Allow | 37 | 4 | 0 | No | No |
| 17592435 | MOLECULAR PROGRAMMING TOOLS | February 2022 | October 2024 | Allow | 32 | 0 | 0 | No | No |
| 17614414 | miRNA MARKER FOR DIAGNOSIS AND/OR TREATMENT OF ALZHEIMER'S DISEASE | November 2021 | April 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17599969 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 INSERTIONS | September 2021 | June 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17377910 | Detection of Shiga Toxin Genes in Bacteria | July 2021 | October 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17366378 | METHOD OF TRANSLOCATING NUCLEIC ACIDS THROUGH NANOPORES | July 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17292965 | AVAPRITINIB RESISTANCE OF KIT MUTANTS | May 2021 | May 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17187211 | Methods and Compositions for Enrichment of Target Polynucleotides | February 2021 | May 2025 | Allow | 51 | 3 | 0 | No | No |
| 17270733 | METHOD FOR ANALYZING FUNCTIONAL SUBUNIT PAIR GENE OF T CELL RECEPTOR AND B CELL RECEPTOR | February 2021 | May 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17173858 | TARGET ENRICHMENT VIA ENZYMATIC DIGESTION IN NEXT GENERATION SEQUENCING | February 2021 | September 2024 | Allow | 43 | 1 | 0 | No | No |
| 17264467 | PARALLEL ANALYSIS OF RNA 5' ENDS FROM LOW-INPUT RNA | January 2021 | June 2025 | Allow | 53 | 1 | 1 | No | No |
| 17134914 | ENZYMATIC SYNTHESIS OF NUCLEIC ACID SEQUENCES | December 2020 | November 2024 | Abandon | 47 | 2 | 1 | No | No |
| 17130852 | CONTROLLED STRAND-DISPLACEMENT FOR PAIRED END SEQUENCING | December 2020 | June 2025 | Allow | 54 | 2 | 1 | No | No |
| 17129147 | PRIMER EXTENSION TARGET ENRICHMENT | December 2020 | June 2025 | Allow | 53 | 3 | 0 | No | No |
| 17122857 | GENETIC TEST FOR DETECTING CONGENITAL ADRENAL HYPERPLASIA | December 2020 | March 2025 | Abandon | 51 | 3 | 0 | No | No |
| 17059773 | MULTIPLEX NUCLEIC ACID DETECTION | November 2020 | July 2024 | Allow | 44 | 1 | 1 | No | No |
| 17101467 | Compositions for the Multiplexed Detection of Viruses | November 2020 | January 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17055167 | POROUS PARTICLE COMPOSITE FOR PCR WITH HEAT DISSIPATION FUNCTION | November 2020 | December 2024 | Allow | 50 | 2 | 1 | No | No |
| 17005496 | METHODS AND SYSTEMS FOR SEQUENCING LONG NUCLEIC ACIDS | August 2020 | December 2023 | Allow | 40 | 2 | 0 | No | No |
| 16991216 | COMPOSITIONS AND METHODS FOR DETECTING AN RNA VIRUS | August 2020 | March 2023 | Allow | 31 | 3 | 0 | Yes | No |
| 16965853 | METHODS AND SYSTEMS FOR VALIDATION OF A NUCLEIC ACID AMPLIFICATION ASSAY | July 2020 | December 2024 | Allow | 53 | 2 | 1 | Yes | No |
| 16957200 | METHOD FOR DIAGNOSING DEPRESSION VIA BACTERIAL METAGENOMIC ANALYSIS | June 2020 | November 2024 | Abandon | 53 | 2 | 1 | No | No |
| 15733166 | METHOD FOR DETERMINING BACTERIAL NUMBER IN SPECIMEN | June 2020 | February 2025 | Allow | 56 | 3 | 0 | No | No |
| 16768881 | FLUID THERMAL PROCESSING | June 2020 | December 2024 | Allow | 55 | 3 | 0 | No | No |
| 16631395 | RAPID THERMOCYCLING METHODS | January 2020 | December 2024 | Allow | 59 | 5 | 0 | Yes | No |
| 16629360 | METHOD FOR DIAGNOSING OVARIAN CANCER THROUGH MICROBIAL METAGENOME ANALYSIS | January 2020 | March 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16682865 | NOVEL METHOD FOR ISOLATING EXTRACELLULAR VESICLES | November 2019 | April 2025 | Allow | 60 | 3 | 0 | No | No |
| 16604956 | DETECTION AND DELINEATION OF MICROORGANISMS | October 2019 | November 2024 | Abandon | 60 | 3 | 1 | No | No |
| 16603981 | SH2B ADAPTER PROTEIN 3 FOR THE PREDICTION OF BONE MARROW RESPONSE AND IMMUNE RESPONSE | October 2019 | December 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 15753132 | Microdroplet-Based Multiple Displacement Amplification (MDA) Methods and Related Compositions | February 2018 | May 2025 | Abandon | 60 | 4 | 0 | No | Yes |
| 15534853 | PRIMER SET AND METHOD FOR AMPLIFYING EXONS OF PKD1 GENE AND PKD2 GENE | August 2017 | August 2019 | Allow | 27 | 2 | 1 | Yes | No |
| 15239542 | HIGH-SENSITIVITY SEQUENCING TO DETECT BTK INHIBITOR RESISTANCE | August 2016 | November 2018 | Allow | 27 | 1 | 0 | Yes | No |
| 14397029 | DETECTION METHOD FOR MYCOBACTERIUM AVIUM SPP. PARATUBERCULOSIS | October 2014 | August 2018 | Allow | 46 | 4 | 0 | Yes | No |
| 14387150 | METHOD FOR IDENTIFICATION AND DETECTION OF MUTANT GENE USING INTERCALATOR | September 2014 | November 2017 | Allow | 38 | 1 | 0 | Yes | No |
| 14109104 | High Resolution Melt Genotyping of IBV, CSFV and NDV | December 2013 | June 2018 | Allow | 54 | 5 | 1 | Yes | No |
| 14000096 | METHOD FOR QUANTIFYING HUMAN DNA | December 2013 | January 2016 | Allow | 29 | 2 | 1 | Yes | No |
| 14055634 | METHODS AND APPARATUS TO SEQUENCE A NUCLEIC ACID | October 2013 | December 2015 | Allow | 26 | 1 | 1 | Yes | No |
| 14043040 | MOLECULAR GRAM STAIN | October 2013 | January 2017 | Allow | 39 | 3 | 1 | Yes | No |
| 13821543 | GENERIC ASSAYS FOR DETECTION OF MAMMALIAN REOVIRUS | August 2013 | January 2017 | Allow | 46 | 3 | 1 | Yes | No |
| 13960548 | INTEGRATED VERSATILE KIT FOR ISOLATING COMPONENTS IN BIOLOGICAL SAMPLES | August 2013 | December 2013 | Allow | 4 | 1 | 0 | Yes | No |
| 13995707 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND DIFFERENTIATING VIRAL COMPONENTS OF MULTIVALENT SHIPPING FEVER VACCINES | June 2013 | September 2015 | Allow | 27 | 3 | 0 | Yes | No |
| 13848759 | METHOD FOR IDENTIFYING OLFACTORY RECEPTOR INCLUDED IN ONE OLFACTORY CELL | March 2013 | August 2014 | Allow | 17 | 1 | 0 | Yes | No |
| 13723315 | MOBILE RAPID TEST SYSTEM FOR NUCLEIC ACID ANALYSIS | December 2012 | October 2015 | Allow | 33 | 1 | 1 | Yes | No |
| 13710192 | METHOD OF CHARACTERIZING VASCULAR DISEASES | December 2012 | June 2016 | Allow | 42 | 3 | 0 | Yes | No |
| 13682071 | QUANTITATION AND PROFILING OF VAGINAL MICROFLORA | November 2012 | December 2017 | Allow | 60 | 5 | 0 | No | No |
| 13501542 | QUANTIFICATION OF IR-A AND IR-B FOR TUMOR CLASSIFICATION | July 2012 | May 2015 | Allow | 38 | 4 | 0 | Yes | No |
| 13263464 | METHOD OF DELIVERING PCR SOLUTION TO MICROFLUIDIC PCR CHAMBER | January 2012 | January 2017 | Allow | 60 | 3 | 0 | Yes | No |
| 13328982 | AUTISM-ASSOCIATED BIOMARKERS AND USES THEREOF | December 2011 | January 2015 | Allow | 37 | 2 | 1 | Yes | No |
| 12979383 | Integrated Versatile and Systems Preparation of Specimens | December 2010 | May 2013 | Allow | 28 | 1 | 1 | Yes | No |
| 12900104 | METHODS FOR REPAIRING DEGRADED DNA | October 2010 | September 2017 | Allow | 60 | 5 | 0 | Yes | No |
| 12881867 | METHOD FOR HLA TYPING | September 2010 | December 2012 | Allow | 27 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner OYEYEMI, OLAYINKA A.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner OYEYEMI, OLAYINKA A works in Art Unit 1681 and has examined 61 patent applications in our dataset. With an allowance rate of 77.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 42 months.
Examiner OYEYEMI, OLAYINKA A's allowance rate of 77.0% places them in the 36% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by OYEYEMI, OLAYINKA A receive 2.15 office actions before reaching final disposition. This places the examiner in the 72% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by OYEYEMI, OLAYINKA A is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +40.0% benefit to allowance rate for applications examined by OYEYEMI, OLAYINKA A. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.9% of applications are subsequently allowed. This success rate is in the 40% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 43.5% of cases where such amendments are filed. This entry rate is in the 60% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 0% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 76.9% are granted (fully or in part). This grant rate is in the 91% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 12.8% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.